Full Text
Is There A Consensus Regarding Clinically Relevant Non-Inferiority Margins Used For Key Oncology Endpoints In Non-Inferiority Oncology Trials?

Abstract

Authors

M Hashim J He P Hu F Soikkeli S Gebregergish B Heeg A Lam

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×